Boston Millennia Partners

Our Firm

Our Team

Our Portfolio

	• Healthcare IT and Business Services

	• Life Sciences

	• Other Investment Successes

Investment Performance

Resources

News



	Richard Love from ILEX Oncology, Inc. on Boston Millennia Partners...

< Home < Life Sciences < Our Team < Our Portfolio

Boston Millennia Partners’ portfolio reflects Millennia’s commitment towards building enduring, large-scale businesses that have the potential to provide superior financial returns to our investors. Millennia’s portfolio is comprised of a diversified group of firms each positioned with the potential to become leaders in their respective market segments. We invite you to use the links below to learn more about each of those portfolio companies.

< Back

  EPIX Pharmaceuticals
  4 Maguire Road
  Lexington, MA 02421
  USA

Phone: 781-761-7600
Fax: 781-761-7641

EPIX Pharmaceuticals, formed from the merger of Predix Pharmaceuticals and Epix Pharmaceuticals, is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has a blood-pool imaging agent approved and marketed in Europe (Vasovist(TM)), and five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include EP-2104R, a novel thrombus imaging agent which has completed a Phase 2a trial, PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, and PRX-03140, which has completed a Phase 1b clinical trial in Alzheimer's patients. EPIX also has collaborations with leading organizations, including Amgen, Cystic Fibrosis Foundation Therapeutics, and Schering AG (Germany).

Millennia Team	Pat Fortune, Ph.D.

Investment Date	January 25, 2005

Visit the Website	http://www.EPIXPharma.com

Related News	Lexington, MA - April 7, 2009 EPIX Pharmaceuticals Commences Exchange Offer for $100 Million Convertible Notes Lexington, MA - March 17, 2009 EPIX Pharmaceuticals Issued Composition of Matter Patent on Novel 5-HT4 Receptor Agonists Lexington, MA - March 5, 2009 EPIX Pharmaceuticals Appoints Elkan Gamzu, Ph.D., as Permanent CEO Lexington, MA - December 22, 2008 EPIX Pharmaceuticals Announces FDA Approval of Vasovist(R) (gadofosveset trisodium) Lexington, MA - September 16, 2008 EPIX Pharmaceuticals Achieves Milestone from Collaboration with Cystic Fibrosis Foundation Therapeutics Lexington, MA - August 5, 2008 Financing Facility May Provide EPIX Up To $50 Million of Capital MarketWatch - July 29, 2008 New Hope for Alzheimer's Patients Lexington, MA - June 11, 2008 EPIX Pharmaceuticals Initiates Second Trial in Phase 2b Program for Alzheimer's Disease Lexington, MA - June 5, 2008 EPIX Pharmaceuticals Achieves Milestone For Third Discovery Program in Collaboration with GlaxoSmithKline Lexington, MA - January 23, 2008 EPIX Pharmaceuticals Achieves $1.25 Million Milestone in Collaboration with Cystic Fibrosis Foundation Therapeutics Lexington, MA - November 12, 2007 EPIX to Raise $16.3 Million through Private Financing Lexington, MA - November 5, 2007 EPIX Pharmaceuticals Achieves Milestone For Second Discovery Program in Collaboration with GlaxoSmithKline Lexington, MA - October 29, 2007 EPIX Pharmaceuticals Reports Preliminary Findings from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate Lexington, MA - October 25, 2007 EPIX Pharmaceuticals Completes Enrollment in Two Key Clinical Trials Lexington, MA - August 28, 2007 EPIX Pharmaceuticals Achieves Milestone in Collaboration with Cystic Fibrosis Foundation Therapeutics Lexington, MA - August 14, 2007 EPIX Pharmaceuticals Achieves Discovery Milestone in Collaboration with GlaxoSmithKline Lexington, MA - August 7, 2007 EPIX Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial Lexington, MA - May 2, 2007 EPIX Announces Retirement of Christopher Gabrieli as Chairman of the Board of Directors Lexington, MA - April 18, 2007 http://investor.epixpharma.com/phoenix.zhtml?c=91717&p=irol-newsArticle&ID=984307&highlight= Lexington, MA - April 12, 2007 EPIX Regains Compliance with NASDAQ, Files Form 10-K Lexington, MA - March 29, 2007 EPIX Pharmaceuticals Initiates Phase 2b Clinical Trial of PRX-00023 in Patients with Major Depressive Disorder Lexington, MA - January 3, 2007 EPIX Pharmaceuticals Secures Patent on Novel 5-HT1A Receptor Agonist and the Treatment of Disorders Associated with Serotonin Action London, Philadelphia & Lexington, MA - December 12, 2006 GlaxoSmithKline and EPIX Pharmaceuticals Enter Drug Discovery and Development Alliance Lexington, MA - December 7, 2006 EPIX Pharmaceuticals Presents Findings from PRX-08066 Clinical Trials at National Institutes of Health Pulmonary Hypertension Meeting Lexington, MA - December 5, 2006 EPIX Pharmaceuticals Initiates Phase 2a Clinical Trial in Patients with Mild Alzheimer's Disease Lexington, MA - October 24, 2006 EPIX Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Clinical Trial of PRX-07034 in Obesity Lexington, MA - October 17, 2006 EPIX Pharmaceuticals Announces Findings from Obesity and Cognitive Impairment Studies at Society for Neuroscience Meeting Lexington, MA - Sept. 20, 2006 EPIX Announces Australian Approval of Vasovist(TM) Lexington, MA - August 16, 2006 EPIX and Predix Pharmaceuticals Complete Merger Lexington, MA - April 19, 2006 Predix Announces Preliminary Results from Phase Ib Trial of PRX-08066 in Hypoxia-Induced Pulmonary Hypertension Cambridge and Lexington, MA - April 3, 2006 Epix and Predix Announce Merger Agreement Woburn, MA - May 3, 2005 Predix Pharmaceuticals Initiates Phase I Clinical Trial of 5-HT2B Receptor Antagonist for Pulmonary Hypertension Woburn, MA - March 30, 2005 Predix Pharmaceuticals Initiates Phase Ib Clinical Trials Of 5-HT4 Agonist For Alzheimer’s Disease And Other Cognitive Disorders Woburn, MA and Bethesda, MD - March 16, 2005 Cystic Fibrosis Foundation Therapeutics and Predix Pharmaceuticals Announce Drug Discovery Collaboration to Treat Cystic Fibrosis Woburn, MA - March 8, 2005 Predix Pharmaceuticals Announces Initiation of Phase II Clinical Trial of its Serotonin 1A Agonist for Generalized Anxiety Disorder Boston, MA – January 25, 2005 Boston Millennia Partners Co-Leads a $43 million Series C in Predix Pharmaceuticals

Our Firm Our Team Our Portfolio Resources News